ArticleNeuro-oncology advances
The dichotomy of central nervous system cancer burden: A global analysis revealing diagnosis-driven epidemics and therapy-resistant mortality.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global burden of central nervous system (CNS) cancers is rising unevenly. Existing studies lack a framework linking macro trends to underlying drivers across scales. Methods: We constructed a "macro-meso-micro" framework, integrating Global Burden of Disease 2021 data (macro perspective) and US SEER registry data (meso perspective). Global/regional/national incidence and mortality trends (1990-2021) were analyzed using descriptive statistics and Bayesian models, alongside subtype-specific clinical patterns. Results: The global age-standardized incidence rate (ASIR) increased from 3.82 to 4.28 per 100,000 population (1990-2021), while the age-standardized mortality rate (ASMR) declined slowly (3.08-3.06), revealing a core "incidence-mortality decoupling." Incidence correlated positively with the socio-demographic index (SDI), but some high-SDI regions achieved superior mortality control, indicating healthcare disparities. SEER data clarified that this plateau was driven by the dismal survival of aggressive subtypes like glioblastoma (GBM), contrasting sharply with the rising detection of benign/low-grade tumors (eg, meningioma). For GBM, standard care has reached a low therapeutic ceiling, with most patients relapsing into a treatment void. Conclusions: CNS cancer burden evolution resulted from multi-scale diagnostic, therapeutic, and biological interactions. Our framework connected macro trends, meso subtype heterogeneity, and micro resistance mechanisms, pinpointing the conquest of therapy-resistant, high-grade tumors (especially GBM) as the central challenge. A translational pathway of "macro surveillance for target identification-clinical problem definition-mechanistic research for breakthrough" was proposed to guide future intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.